New Anti-Clotting Drug Asundexian Shows Promise in Reducing Stroke Risk
A recent phase III trial has revealed that the investigational anti-clotting drug Asundexian, developed by Bayer, significantly reduces the risk of stroke by 26% without increasing the risk of major bleeding. The trial, involving 12,327 adult patients from 37 countries, focused on individuals who had experienced a non-cardioembolic stroke or transient ischaemic attack. Participants were administered Asundexian alongside standard antiplatelet therapy, such as aspirin. The results showed a notable reduction in ischemic strokes and major cardiovascular events among those taking the drug compared to a placebo group. The trial's principal investigator, Mike Sharma, emphasized the potential of Asundexian in providing safer long-term stroke prevention. 
